Revance Therapeutics Inc (NASDAQ:RVNC) has a beta value of 0.99 and has seen 2.46 million shares traded in the recent trading session. The company, currently valued at $685.50M, closed the recent trade at $6.58 per share which meant it lost -$0.01 on the day or -0.15% during that session. The RVNC stock price is -176.75% off its 52-week high price of $18.21 and 65.05% above the 52-week low of $2.30. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.16 million shares traded. The 3-month trading volume is 3.72 million shares.
The consensus among analysts is that Revance Therapeutics Inc (RVNC) is Buy stock at the moment, with a recommendation rating of 2.67. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 8 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.38.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Revance Therapeutics Inc (NASDAQ:RVNC) trade information
Over the past 30 days, the shares of Revance Therapeutics Inc (NASDAQ:RVNC) have changed 115.03%. Short interest in the company has seen 9.26 million shares shorted with days to cover at 1.65.
Wall Street analysts have a consensus price target for the stock at $17.5, which means that the shares’ value could jump 62.4% from the levels at last check today. The projected low price target is $8.0 while the price target rests at a high of $37.0. In that case, then, we find that the latest price level in today’s session is -462.31% off the targeted high while a plunge would see the stock gain -21.58% from the levels at last check today.
Revance Therapeutics Inc (RVNC) estimates and forecasts
The company’s shares have gained 1.23% over the past 6 months, compared to 17.60% for the industry. Revenue growth from the last financial year stood is estimated to be 17.70%.
8 analysts offering their estimates for the company have set an average revenue estimate of 68.2M for the current quarter. 8 have an estimated revenue figure of 88M for the next ending quarter. Year-ago sales stood 56.78M and 69.8M respectively for this quarter and the next, and analysts expect sales will grow by 20.10% for the current quarter and 17.70% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 0.57% over the past 5 years. Earnings growth for 2024 is a modest 49.09% while over the next 5 years, the company’s earnings are expected to increase by 11.60%.
RVNC Dividends
Revance Therapeutics Inc is expected to release its next earnings report in October this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Revance Therapeutics Inc (NASDAQ:RVNC)’s Major holders
Insiders own 8.58% of the company shares, while shares held by institutions stand at 84.77% with a share float percentage of 92.72%. Investors are also buoyed by the number of investors in a company, with Revance Therapeutics Inc having a total of 239.0 institutions that hold shares in the company. The top two institutional holders are CAPITAL WORLD INVESTORS with over 13.94 million shares worth more than $35.82 million. As of 2024-06-30, CAPITAL WORLD INVESTORS held 15.164% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 8.57 million shares as of 2024-06-30. The firm’s total holdings are worth over $22.01 million and represent 9.3183% of shares outstanding.
